BIOCORP acquired by NOVO NORDISK

Elos Medtech entered into an agreement to acquire 100% of Klingel Medical Group from IK Partners and its management team. The strategic rationale for the deal is to create a market-leading European MedTech CDMO with significantly enhanced R&D capabilities and a broader technological offering. The acquisition expands Elos Medtech's industrial presence in the DACH region by adding eight specialized manufacturing sites in Germany and Switzerland. Strategically, the combination aims to unlock cross-selling opportunities and provides Klingel with increased visibility and distribution channels in the U.S...

EQT completed the take-private acquisition of Dechra Pharmaceuticals. The strategic rationale for taking Dechra private was to support its long-term growth away from the volatility of public markets. In early 2023, Dechra faced headwinds from "wholesaler de-stocking" in the US, which hit its share price. EQT intends to accelerate investment in the company's innovation pipeline and support further international acquisitions without the pressure of quarterly earnings reporting.

The successful acquisition of AprioMed by IZI Medical Products represents a tactical expansion of Halma’s healthcare portfolio in the interventional radiology segment. This transaction marks the integration of AprioMed’s highly specialized bone biopsy technology, effectively widening the technical operational depth available to IZI Medical’s global clinical customer base. The strategic rationale centers on the industrial synergy between AprioMed’s minimally invasive instruments and IZI Medical’s established oncology and radiology portfolio, allowing for a more verticalized patient diagnosis solution

Sartorius Stedim Biotech has reached a definitive agreement to acquire one hundred percent of the share capital of Polyplus from private equity sponsors ArchiMed and Warburg Pincus. This landmark transaction is structured as a full buyout, effectively transferring ownership from financial sponsors to a strategic corporate acquirer. The operation is financially underpinned by a bridge loan facility secured by the acquirer's parent company through J.P. Morgan, which is expected to be ultimately refinanced via long-term financial instruments potentially incorporating an equity component

Ardian has acquired a stake in Théradial, a specialized player in the French dialysis sector, with a consolidated presence in medical product distribution, pharmaceuticals, and healthcare software. This transaction is part of a strategic partnership with UI Investissement, which had previously invested in the company in 2017. Founded in 1998, Théradial employs around 90 staff in France and Italy, generating approximately 50 million euros in revenue, primarily from public healthcare establishments, private clinics, and home care service providers

Unither Pharmaceuticals, a global leader in sterile single-unit dosage manufacturing, has undergone a capital reorganization led by its management team and a consortium of prominent investors. GIC and IK Partners have entered as new equity partners, while Keensight Capital and Parquest are reinvesting to reinforce their existing positions. The consortium is acquiring the majority stake from Ardian, following a successful five-year partnership.

Stanley Capital Partners acquired a majority stake in Laboratoire X.O following the liquidation of its former owner, Novalpina Capital. The deal resolved a year-long legal dispute between management and transitional managers (BRG). This new phase focuses on a strategic merger with Noden Pharma (another SCP portfolio company), providing X.O with a commercial platform in Ireland and the United States. The goal remains to triple revenue within 3-4 years through aggressive portfolio acquisitions.

Catalent has executed a definitive binding agreement to acquire Metrics Contract Services, a specialized CDMO subsidiary, from Australia-based Mayne Pharma Group. Concurrently with the main transaction, the parties established a five-year commercial supply agreement alongside a transition service agreement (TSA), ensuring a seamless operational integration and absolute supply continuity for the divesting parent’s retained product portfolio. This transaction represents a highly value-accretive platform investment purposefully designed to expand integrated global oral solid formulation capabilities

Healthcare-focused investment firm Mérieux Equity Partners has completed the strategic merger of two of its existing portfolio companies, Addmedica and Laboratoires CTRS, creating a new consolidated entity named Theravia Pharma. As part of this corporate combination, the sponsor—which already held existing stakes in both businesses—elected to significantly increase its overall equity position. Mérieux EP rolled over its historical shares and convertible bonds while simultaneously acquiring additional equity, notably buying out the exiting founders of Addmedica

TPG Capital has signed a binding agreement to acquire a majority stake in DOC Generici from ICG and Mérieux Equity Partners. The strategic rationale for the transaction is driven by the continued expansion of the Italian generic drug market and DOC Generici's position as a reference brand for patients and healthcare providers. TPG intends to partner with the existing management team to accelerate the company’s leadership through significant investment in organic growth and external consolidation